No Detail Found!

Investigation of CD8, CD20 and their Correlation with Heat Shock Protein 90 in Breast Cancer Patients

Author(s)
Tuqa Alaa Nuaman Department of Biology, College of Medicine, Aliraqia University, Iraq
Hayfaa Mahmood Fahad Department of Biology, College of Medicine, Aliraqia University, Iraq
Abstract
Objectives: Background: One of the main causes of cancer-related fatalities globally, breast cancer is the most prevalent malignancy in women. Many individuals are still detected at advanced stages and its occurrence keeps rising due to lifestyle, hormonal and hereditary factors. The disease is biologically diverse, with molecular subtypes (luminal, HER2positive, triple-negative) that influence prognosis and therapy. Despite progress in screening and targeted treatments, recurrence and therapy resistance remain major challenges, highlighting the need for new prognostic markers and improved therapeutic strategies. Objective: Analytic immunological markers for assessment of prognostic values of CD8, CD20 and their correlation with heat shock protein 90 in breast cancer. Methods: Al-Iraqi University's College of Medical Sciences gave its approval for the project. The trial, which lasted three months (November to February 2025), involved 140 females from the medical city (Oncology Educational Hospital) who donated three ml of their blood divided into two sets of participants. One group consisted of 70 patients with breast cancer, while the other group consisted of 70 healthy people. Serum levels of CD8, CD20 and HSP-90 were estimated using ELISA assays. Participants in the study provided demographic information, including age, sex, family history and medical history. Results: The study samples ranged in age from 19 to 85 years, with a mean of 49.86±12.713. The majority of the sample (46.4%) was in the 46-60 age range. The mean levels of CD8 and CD20 were significantly higher (18.93541±4.743529 Vs 4.82896±1.858044), with significant mean differences of -14.106457 (t = -23.167, df138, p = 0.000) for CD8 and (1.71293±0.212769 Vs 0.91524±0.206988), with significant mean differences of - 0.797686 (t = -22.483, df138, p = 0.000) for CD20.The mean value of HSP-90 was significantly higher (47.85257±3 8.893877 Vs 14.57260±5.176012), with a significant mean difference of -33.279971 (t = -27.058, df: 138, p = 0.000) respectively. Conclusion: CD8, CD20 and HSP-90 can be used to evaluate the immune response of breast cancer disease patients and serve as a marker for early diagnosis.
Publication Details
Page(s) 143-150
DOI DOI not available
Published Journal: Journal of Pioneering Medical Sciences, Volume: 15, Issue: 2, Year: 2026

Request the full text from PASTIC

Keywords
HSP-90, CD20, CD8, Breast Cancer
References
.2024 .. , : .
United Nations Office The .2025 .Breast Cancer Cases Projected to Rise by Nearly 40 Per Cent by 2050. , : .
Kuroda H. .2021 .Tumor-infiltrating B cells and T cells correlate with postoperative prognosis in triple-negative carcinoma of the breast. ” BMC Cancer, 21(1) : .
Jääskeläinen M.M. . .The prognostic and predictive role of tumor-infiltrating lymphocytes (FoxP3+ and CD8+) and tumorassociated macrophages in early HER2+ breast cancer. ” Breast Cancer Research and Treatment, 201(2023) : 1-10.
Yazaki S. . .Integrative prognostic analysis of tumorinfiltrating lymphocytes, CD8, CD20, programmed cell death-ligand 1 and tertiary lymphoid structures in early-stage triple-negative breast cancer without adjuvant chemotherapy. ” Breast Cancer Research and Treatment, 197(2022) : 287-297.
Lin T. .2020 .Heat shock protein 90 family isoforms as prognostic biomarkers and their correlations with immune infiltration in breast cancer. , : 1-15.
Birbo B. .2021 .Role of HSP90 in cancer. International Journal of Molecular Sciences, 22(19) : 10317.
Hong L. .2024 .HSP90 promotes tumor-associated macrophage differentiation during triple-negative breast cancer progression. ” Scientific Reports, 14(1) : .
Safiri S. .2022 .Burden of female breast cancer in the middle East. , 80(1) : 1990-2019.
Feng J. .2022 .Peripheral blood lymphocyte subtypes as new predictors for neoadjuvant therapy efficacy in breast cancer. ” Cancer Medicine, 11(15) : 2923-2933.
Sun Y.P. .2022 .Prognostic value of CD8+ tumor-infiltrating T cells in patients with breast cancer: A systematic review and meta-analysis. ” Oncology Letters, 25(1) : .
Li M. .2022 .Predictive and prognostic role of peripheral blood T-cell subsets in triple-negative breast cancer. ” Frontiers in Oncology, 12 : .
Luque M. .2022 .Tumor-infiltrating lymphocytes and immune response in HER2-positive breast cancer. ” Cancers, 14(24) : 6034.
Hamed M.M. .2022 .Evaluation of PD-L1, CD8 and CD20 as early predictive and tracking markers for breast cancer in Egypt. ” Heliyon, 8(5) : .
Rastogi S. .2024 .An update on the status of HSP90 inhibitors in cancer clinical trials. ” Cell Stress and Chaperones, 05(2024) : 519-539.
Falcone I. .2025 .HER2-driven breast cancer: Role of the chaperonin HSP90 in modulating response to trastuzumabbased therapeutic combinations. International Journal of Molecular Sciences, 26(14) : 6593.
Q. .2012 .Amplification and high-level expression of heat shock protein 90 mark aggressive phenotypes of human epidal growth factor receptor 2-negative breast cancer. ” Breast Cancer Research, 14(2) : .
0

Citations

0

Downloads

16

Views